

**REPORT
SUSTAINABILITY
2021**

SUMMARY

Report presentation

Leadership message

1. INTRODUCTION

About Amgen

Awards and recognitions

Our ESG approach

2. COMBATING COVID-19

Internal assistance

3. HEALTHY PEOPLE

Access to health

4. HEALTHY SOCIETY

Human capital management

Diversity, inclusion
and belonging

Social responsibility

5. HEALTHY PLANET

Environmental sustainability

6. A HEALTHY AMGEN

Corporate governance

Business ethics

Ethical research and innovation

Data privacy and cyber security

REPORT PRESENTATION

In Amgen Brazil's 2021 Sustainability Report, we present our most relevant numbers and initiatives of the year, regarding social, environmental and governance responsibility.

In an objective format, we share initiatives carried out and goals for the coming years, aligned with the Amgen team around the world. We are building our sustainability strategy, based on a global company commitment. And maintaining this report is a practical part of that activity.

The report is divided into six chapters. At **Introduction**, we present our mission and history, as well as relevant highlights. We highlight our COVID-19 prevention actions with our employees.

In the following chapters, we deal with patients, society, the planet and the company in a perspective that seeks the well-being and health of all these

links. This is a vision we share with all Amgen locations, because for us it's important to establish this relationship between the global and the local.

In this report, we also seek to deepen the management approach of our material issues - those that reflect our impacts on the world - established globally in 2020, allowing us to report them using the SASB (Sustainability Accounting Standards Board) methodology in the future, as we already do in Amgen Global operations.

For those who wish to share with us their doubts, questions and other comments, we provide the email sacbrasil@amgen.com. It is our commitment to dialog with stakeholders in order to improve, year after year, the quality of our management and reporting.



LEADERSHIP MESSAGE

In another year, we have gathered the sustainability results in a report that shows our strategy and concern for social, corporate and environmental responsibility at Amgen Brazil. From this document, we want to show how the engagement of our team within this theme can contribute to the construction of a more sustainable Brazil.

We understand that serving patients is also taking care of society and the environment where they live. To this end, we develop diversity and inclusion actions, support patient association projects and set goals to reduce our environmental impact.

In this publication, we present our company and everything we believe

in to develop an organization with even greater integrity and social responsibility. In addition to our history of more than 10 years in Brazil, we bring here our sustainability actions, relevant aspects of ethical research and innovation, access to medicine, among other subjects.

It is a joy to look at 2021 and realize that, even living with the challenges of this year still affected by the COVID-19 pandemic, we managed to move forward. We have been connected with our patients on several fronts to promote access to healthcare and increase awareness and prevention.

Bringing together all the initiatives, actions and campaigns, we realize the

path we have already taken and how much our employees are involved in our achievements. This survey also helps us to see where we need to advance in the environmental, social and governance aspects.

Our ambition is to make Amgen Brazil an increasingly better company to work for. It is also our desire to strengthen our sustainability journey, so that together we can contribute to an increasingly healthy world, in every way.

Elvin Penn
General Manager of Amgen Brazil



INTRODUCTION

ABOUT AMGEN

We are one of the largest independent biotechnology companies in the world. Our commitment is to use the potential of biology to benefit patients in complex treatments. At Amgen, we discover, develop and manufacture innovative therapies.

We believe that medicines not only help patients, but also contribute to reducing the social and economic burden caused by diseases on society. We focus our work on drugs that address areas where medicine has yet to advance. Our portfolio includes drugs in

the following therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. All drugs are available at the link: <https://www.amgen.com.br/products/about>.

Globally, Amgen was born in 1980, in California (USA), but we arrived to Brazil in 2009, with the opening of the first clinical research office in South America. In 2011, we acquired the Bergamo Laboratory and expanded our operations in the country.



DRUGS MARKETED IN

100
countries

OVERALL REVENUE

US\$ 26
billion

INVESTMENT IN RESEARCH & DEVELOPMENT

In the world
US\$ 4,8
billion

In Brazil
R\$ 9,7
million

COLLABORATORS

In the world
24.000

In Brazil
448

MISSION AND VALUES

Our mission is TO SERVE PATIENTS.

**That's why we don't measure efforts to serve each patient.
We want science in therapies that have the power to restore
health and save lives.**

And to fulfill this mission, we are guided by eight values:

BE SCIENCE-BASED

COMPETE INTENSELY AND WIN

CREATE VALUE FOR PATIENTS, STAFF AND STOCKHOLDERS

BE ETHICAL

TRUST AND RESPECT EACH OTHER

ENSURE QUALITY

WORK IN TEAMS

COLLABORATE, COMMUNICATE AND BE ACCOUNTABLE

AWARDS AND RECOGNITIONS IN 2021



World's Best Workplaces for 2021™ [Best Companies to Work for™]

Amgen was selected as one of the best companies to work for in the World for 2021. Recognition is given by **Fortune** magazine. Amgen ranked eighth out of 25 companies nominated for the list, which were selected from 10,000 companies representing the voices of nearly 20 million employees in more than 100 countries.

America's Most Just Companies

Amgen was named one of the "JUST 100" by **Forbes** and **JUST Capital** in their annual rankings of America's Most Just Companies. To arrive at these ratings, **JUST Capital** surveyed more than 100,000 Americans on issues that define fair business behavior.

The Best-Managed Companies of 2021

Amgen ranked 37th on **The Wall Street Journal's** annual list of the 250 best-managed companies for 2021. The **WSJ's Management Top 250 ranking**, developed by the Drucker Institute, measures corporate efficacy in five key areas: customer satisfaction, employee engagement and development, innovation, social responsibility and financial strength.

2021 Dow Jones Sustainability Indices


Amgen ranked among the top biotechnology companies for corporate responsibility by the **Dow Jones Sustainability Indices (DJSI)** 2021 for the eighth consecutive year in the world *rankings*; and for the ninth consecutive year, in the North America ranking. These **DJSI** indexes are among the most robust and reliable indicators of a company's sustainability performance due to the breadth of the companies included and the extensive and rigorous nature of their annual assessment.

OUR ESG APPROACH

Serving patients is not a mission that is limited to the elaboration of therapies. We are committed to helping build a better world through actions on environmental, social and governance (ESG) issues.

In the environmental pillar, we are adapting the global strategy for Brazil

with the goals set for 2027. In them, we seek to reduce water consumption and waste, in addition to neutralizing our carbon emissions in Scope 1 and 2. The strategy to achieve these goals is still under construction, but all initiatives already carried out in 2021 have this commitment.



* Scope 1 and 2 relates to emissions from Amgen owned and operated facilities and operations.

Amgen's sustainability management globally supports and contributes to the United Nations' Sustainable Development Goals (SDGs). Of the 17 SDGs, Amgen Brazil believes that it can collaborate, mainly, with the achievement of seven of them, which are the most adherent material themes:

3
GOOD HEALTH AND WELL BEING

GOOD HEALTH AND WELL-BEING: ensure healthy lives and promote well-being for all at all ages.

8
DECENT WORK AND ECONOMIC GROWTH

DECENT WORK AND ECONOMIC GROWTH: promote sustained, inclusive and sustainable economic growth, full and productive employment and decent work for all.

5
GENDER EQUALITY

GENDER EQUALITY: achieve gender equality and empower all women and girls.

9
INDUSTRY, INNOVATION AND INFRASTRUCTURE

INDUSTRY, INNOVATION AND INFRASTRUCTURE: build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation.

12
RESPONSIBLE CONSUMPTION AND PRODUCTION

RESPONSIBLE CONSUMPTION AND PRODUCTION: ensure sustainable consumption and production patterns.

13
CLIMATE ACTION


CLIMATE ACTION: take urgent action to combat climate change and its impacts.

17
PARTNERSHIPS FOR THE GOALS

PARTNERSHIPS FOR THE GOALS: strengthen the means of implementation and revitalize the Global Partnership for Sustainable Development.



COMBATING COVID-19



INTERNAL ASSISTANCE

Even with the start of vaccination against COVID-19 and the decrease in the number of cases of the disease, we continue to follow preventive measures. Our prompt adaptation was essential for us to continue working at Amgen Brazil units, ensuring the health and safety of our employees and their families.

It is the company's global Crisis Committee that discusses the impacts of the pandemic and how we should act. Since the announcement of the spread of the virus, we have sought to invest in monitoring actions, in addition to technology and personal protective equipment.

During 2021, we carried out several actions to ensure everyone's well-being. One of the high-impact actions to implement this culture of prevention in the company was the "Daily Safety Dialog", a practice known as DDS. Throughout the year, the DDS talked about support for our employees, prevention, care and the correct procedure in case of contagion.

All individual hygiene measures were reinforced, with the distribution of alcohol gel and masks, in addition to guidance boards scattered throughout all units. The movement of people in the factory, as well as access to meeting rooms, restaurant and pantry were restricted. Employees who were pregnant and employees with comorbidities or chronic illnesses began working remotely.

Through daily questionnaires and monitoring *tag* - a *software* that identifies and alerts to the safe distance between employees -, we follow up on suspected and confirmed cases of the disease. Employees also had medical and psychological support, either remotely or in person.

Internally, we also promoted lectures and campaigns that answered questions and encouraged vaccination against COVID-19.

"Since the emergence of the coronavirus, we have created a local crisis committee - fully aligned with the global committee - to manage matters related to the pandemic and guide us in decision-making to face the disease. Always based on science and information from local and global authorities, our priority has been to ensure the health, physical and emotional well-being of all our employees, while ensuring the continuity of our operations, making our medicines to continue reaching our patients without interruption. Our resilience was critical for us to continue to pursue our mission of serving patients."



JHONATHAN BARRETO, EHSS MANAGER AND CRISIS COMMITTEE LEADER (IMT) FOR LATIN AMERICA

HEALTHY PEOPLE



ACCESS TO HEALTH

At Amgen, we seek to develop therapies that guarantee quality with safety and attractive prices to promote sustainable access to patients and also to public administration.

With this objective in mind, our strategy at Amgen Brazil has as one of its priorities the development of biosimilars, which are medicines with a structure similar to that of the original biologicals. They are clinically equal in terms of safety, efficacy, and ability to elicit an immune response.

We believe that a class of drugs with the same clinical outcome, but at a reduced cost, benefits everyone involved in healthcare treatments.

Currently, Amgen has 17 approved molecules and 14 commercialized in the Brazilian market.

In 2021, we approved another product in Brazil, a drug that treats diseases such as lymphoma, rheumatoid arthritis and leukemia. Thus, we reached 18 approved products and 15 being sold. We also develop projects that expand access to medicine through patient associations.

During the year, we supported 13 projects from eight different institutions. We invested R\$ 873,000, benefiting more than 350,000 people in guidance, prevention and awareness campaigns.

We also contributed to the dissemination of the use of biosimilars, reaching as a result more than 170 thousand units sold to the public market.

“Novel therapies are needed to improve outcomes for KRAS-mutated non-small cell lung cancer (NSCLC) patients after progression to first-line treatment. Amgen has facilitated, through clinical studies and an Expanded Access Program, Brazilian patients to have access to one of its most innovative therapies in this type of treatment.”

ALEJANDRO ARANCIBIA, DIRECTOR OF THE MEDICAL AREA



PATIENT SUPPORT

In our relationship with patients, we always want to be close. Therefore, at Amgen Brazil, we have created a Patient Support Program (PSP), *BemPerto®*, which offers exclusive and free assistance to patients using their medications, in addition to assisting caregivers and doctors.

In 2021, we invested R\$ 3.5 million in the Patient Support Program (PSP), benefiting more than 35,000 people. *BemPerto®* provides support on diagnosis and treatment, access to medication, monitoring of adherence to therapy and offers information about the disease and treatment.

Each pathology has a specific program, whether for patient, caregiver or doctor. Discover the programs:

VERY CLOSE TAKING CARE OF YOU

VERY CLOSE TO THE ONE YOU LOVE

VERY CLOSE TO YOUR FREEDOM

VERY CLOSE TO YOUR TOMORROW

VERY CLOSE TO YOUR HEART

VERY CLOSE TO YOUR WELL-BEING



LEARN MORE ABOUT THESE PROGRAMS AT
<https://programabemperto.com.br/>



HEALTHY SOCIETY



HUMAN CAPITAL MANAGEMENT

Valuing our team of employees is one of Amgen Brazil's priorities. With the change of scenery caused by the pandemic, we have been working remotely for over a year with most of the team. This new reality brings physical and mental impacts, which the company seeks to mitigate, causing changes in *mindset*.

One of the initiatives we implemented in this regard was the *Work Empowered* methodology, which introduced solutions and experiences to help evolve the way we work and better meet our personal and professional needs.

To help with this task, *Work Empowered* has identified five key objectives that, as we move forward together, help guide our focus: Collaboration, Flexibility, Alignment, Connection and Time to Focus. Based on them, we work on actions that boost the quality of life, well-being, productivity and team spirit of our team.

Among the practices of valuing human capital within the company, the main concern is directed to actions in favor of mental health. During the year, we produced lectures on stress management, the role of science in improving quality of life and how to maintain sanity in a prolonged period of pandemic.

We also provide a psychologist specializing in grief for conversation circles, in addition to offering online care from psychology professionals and a grief support service through apps.

All new employees went through virtual *onboardings* to learn about our internal processes and receive a welcome from the company on their arrival. During the year, we promoted three *workshops* for team development and a series of lectures and events to discuss diversity, inclusion and belonging.

DIVERSITY, INCLUSION AND BELONGING

At Amgen, we believe that an inclusive environment fosters innovation and drives our ability as a company to better serve patients.

Working with diversity, inclusion and belonging is one of the principles we adopt and value. In a society with such expressive inequalities, this is a priority issue for us.

Globally, Amgen has a respected history of diversity. In Brazil, we started our project in October 2019. In our strategic plan, we made 10 commitments:

- Agendas related to the subject must be mandatory topics to be discussed at Amgen Brazil leadership committee meetings.
- Prioritize the hiring of minority groups and promote an environment of psychological safety, ensuring a sense of belonging to all.
- Promote programs that accelerate the careers of female employees and prioritize women for executive positions.
- Promote internal campaigns on women in science and establish external partnerships to act in the fight against prejudice against women in science.
- Establish partnerships with specialized selection companies and have at least one black candidate on all selection *shortlists*.
- Direct 50% of vacancies from field team expansion projects to black people.
- Convert paternity leave and maternity leave to parental leave, equaling the period to 180 days, also extended in cases of adoption.
- The daycare assistance policy is extended to all employees with children up to 36 months of age, as well as in cases of adoption.
- Commitment to psychological safety, implementing the parental journey to promote reception with the arrival of a new child.
- Extend the educational subsidy to technical courses and graduations, previously only directed to graduate courses.



“Diversity, inclusion and belonging at Amgen is about how each of us can take responsibility for creating a welcoming, inclusive and productive work environment in which all our employees feel valued, regardless their differences, and are able to contribute to their full potential. We are on a journey of much learning and aware that there is still much to do. However, I am confident that we are on the right path, executing our strategic plan and the 10 D, I & B Commitments (Diversity, Inclusion & Belonging), contributing to the achievement of expressive results.”



THIAGO PASTORE, DIRECTOR OF HUMAN RESOURCES

We are in a phase of intense learning, knowing that the road is long and that we still have a long way to go. In addition to our commitments, since 2020, we have also worked with affinity groups that represent the causes of diversity in gender, race, people with disabilities and LGBTIA+.

and ensure a work environment with a strong sense of belonging. Leaders and allies underwent training given by the *Mais Diversidade* consultancy.

Grupos de afinidade:

WE2 - AIMED AT FEMALE EMPOWERMENT



ABEN - AIMED AT RACIAL ISSUES


ABLE - AIMED AT PEOPLE WITH DISABILITIES

PRIDE - AIMED AT LGBTIA+ ISSUES



The members of these groups promote thematic weeks, conversation circles, lectures and educational actions, in addition to reviewing internal policies and procedures, always seeking to make the organization more inclusive

DIVERSITY IN LEADERSHIP POSITIONS



invest in initiatives and projects that help us to live in a more just society.

Amgen Brazil's Social Responsibility Committee supported six projects from patient associations and the community in 2021.

Among the projects that received support are:

- Donations to the NGO Obra do Berço, which promotes social assistance actions aimed at communities in the capital of São Paulo.
- Donations to the São Judas Tadeu Orphanage, which welcomes, educates and supports vulnerable children and adolescents in the city of São Paulo.
- In the Seals and Plastic Caps donation campaign, the Instituto União Sem Fronteiras (UNISF) received 18.2 kg of plastic caps and another 7 kg of aluminum seals. With the sale of recyclable material, the institute reverses the amount collected and uses it for the benefit of children, adolescents, young people and women in socially vulnerable situations in São Paulo.
- Organization of the 2nd Volunteering Week, with the participation of 150 volunteers in virtual and face-to-face actions. On "Impact Day", 50 employees took a day off work to participate in social actions. During the week, another 30 employees also signed up for the blood donation campaign.
- The *Amé Gente* campaign collected donations of warm clothing, R\$ 2 thousand and 36 basic and cleaning baskets for Instituto Sonhe!, which serves residents of Cracolândia, in São Paulo.
- In the Children's Day campaign, we collected 160 toys for *Fundação Gibi* and 15 kg of damaged toys for recycling with *Terra Cycle*.
- We held an informative *webinar* on elderly care, in partnership with the Mais Vívda institution, which helps elderly people in their relationship with technology. More than 100 participants were registered.
- We promoted a Christmas Campaign, collecting sweets and R\$ 12,000 for children from families served by *Instituto Gabi*, which assists children with disabilities in socially vulnerable situations.



SOCIAL RESPONSIBILITY

At Amgen Brazil, we want to make a difference in people's lives, and this goes beyond producing quality medicines. Each year, we dedicate important resources to building a better world.

Our impact reaches diverse sectors such as hospitals, patient associations and communities. We believe that impacting these groups requires our active participation, which is why we

HEALTHY PLANET



ENVIRONMENTAL SUSTAINABILITY

Our quest to reduce environmental impacts is global and started in 2007. We continue to expand this planning in the Brazilian operation, starting a new cycle of global goals for 2027.

Since 2007 we have reduced carbon emissions by 33%, but our ambition is to reach *net zero* within the next six years. In this period, we also intend to reduce water consumption in our operations by another 10% and reduce our waste production to 75%.

Among the actions we took to make this sustainable journey, we planted 451 native trees in 2021, through our Bergamo business unit, of which the Laboratory is part. These trees are capable of absorbing 63 tons of

greenhouse gases (GHG). The initiative earned us the certificate of *Empresa Amiga da Floresta* from the *Instituto Brasileiro de Florestas*.

Reverse logistic

We participate in Sindusfarma's collective reverse logistics plan for post-consumption drugs. Currently, we have more than 100 collection points in the state of São Paulo, in 24 cities. In 2021, we collected 247.5 kg of correctly disposed medicines.

We also have a collection point to serve employees and visitors at our factory. We collect, on average, one kilo of discarded medicines per month.

"The development of transport solutions that contribute to the reduction of waste generation for the environment needs to be increasingly present in companies. We here at Amgen are doing our part and by 2022 we will reduce material waste by more than 80 tons, contributing to the organization's global 2027 goal and more sustainable local operations."

DANIEL CACITA, SUPPLY CHAIN HEAD BRAZIL



CONSUMPTION IN 2021



ENERGY

Total consumption

**6.207.546
KWh**

100% of the electricity consumed by the factory comes from renewable sources and **20%** from biomass.



WATER

Total consumption

24.679 m³

The water consumed is supplied by the utility company. Of this total, **19.743 m³** is disposed of in effluent with its own treatment, **13%** is consumed in the process and **7%** is lost in evaporation.



EMISSIONS

Total direct emissions (scope 1)

**286,2 ton of
CO₂ e**

Total direct emissions (scope 2)

**569,97 ton
of CO₂**


WASTE

The total amount of non-hazardous waste was **116,915 kg**, of which **40,429 kg** were destined for recycling, **580 kg** for treatment and **75,916 kg** for landfill. The total amount of hazardous waste was **43,678 kg**, of which **27,222 kg** were destined for incineration, **15,531 kg** for co-processing and **925 kg** for treatment.



REFRIGERATED TRUCK

We are implementing, at Amgen Brazil, the use of refrigerated trucks for the distribution of medicines. The transport of drugs needs to respect a series of storage rules, as they are sensitive to variations in lighting, humidity and temperature.

In Brazil, our medicines were transported in isothermal packages, but the use of new trucks allows us to meet our goals. With them, we estimate to reduce 80 tons of packaging disposal by 2027, in addition to generating savings of US\$ 200,000.

By November 2021, with the start-up of 10 refrigerated trucks, we stopped discarding six tons of plastic packaging and generated savings of US\$ 20,000.

A HEALTHY AMGEN



BUSINESS ETHICS

It is our commitment to conduct business ethically and transparently, ensuring compliance with pharmaceutical industry laws and regulations. The company's leadership is committed to promoting an ethical culture, seeking to value people, integrity and results.

Our Global Compliance and Business Ethics Program is based on our values ([see page 7](#)). At Amgen, we believe it's

everyone's responsibility to do the right thing to conduct business ethically.

We provide a number of resources to help employees in this regard, including: the Code of Conduct; compliance websites and training courses; internal compliance policies; guidance from dedicated managers and professionals; and the Amgen Business Conduct Hotline, over the Internet and by phone.

STANDARDS OF CONDUCT

Amgen's Standards of Business Conduct provide important tools to ensure they "do the right thing" in all corporate practices.

All collaborators must:

- **understand and adhere to the Code of Conduct;**
- **seek clarification when in doubt about compliance;**
- **report a concern when a violation is suspected;**
- **use common sense;**
- **and act with honesty and integrity.**



[ACCESS THE COMPLETE CODE OF CONDUCT](#)

All Amgen's business ethics standards are in accordance with the Pharmaceutical Research Industry Association (Interfarma) and the Pharmaceutical Industry Union of the State of São Paulo (Sindusfarma).

We also adhere to the UN Global Compact, supporting the 10 principles that encompass Human Rights, Labor Rights, Environmental Protection and Anti-Corruption.

CORPORATE GOVERNANCE

At Amgen Brazil, we are managed actively and passively by two directors, one being a CEO and a director responsible for all administrative acts of the company.

Responsible leadership

Our Global Business Ethics and Compliance Program promotes a culture of ethics and compliance, developing trusted and collaborative partnerships across all aspects and levels of our business. And to ensure the strengthening of this culture, we have a responsible leadership that defends this corporate commitment.

- Board of Directors Corporate Responsibility and Compliance Committee (CRCC): final oversight body for Amgen's Global Business Ethics and Compliance Program.

The group periodically evaluates management's implementation and continuous improvement, including reports and allegations of suspected misconduct and the company's response.

- Compliance Committee: defends the culture of compliance and ethics in business, ensuring that it is the basis of the company's strategy, goals and objectives.
- Compliance Council: multifunctional body that analyzes compliance activities and obligations, implements Program improvements and provides information to the Compliance Committee and the Corporate Responsibility and Compliance Committee of the Board of Directors.



ETHICAL RESEARCH AND INNOVATION

Our commitment is to develop new therapies to treat serious diseases, a long process that requires technical and regulatory compliance with several standards. Thus, dedication and commitment to the scientific research process in all its phases is required.

It all starts with pre-clinical research, when we look for a molecule with the

potential to cure or treat some disease. In 2021, we managed 124 molecule development programs around the world, 21 of them in Brazil.

After this stage, we started another also fundamental stage for the production of a new drug, clinical research. Through this analysis, we evaluate treatments, tests

and the effects of each drug on human health. With volunteers, we conduct clinical trials to test medical interventions, including drugs, cells and other biologics, surgical procedures, radiological procedures, devices, behavioral treatments, and preventative care.

In 2021, we work on five clinical studies in Brazil, with more than 200 volunteers. In this year, we also developed and approved a new drug in the country.


Our research at Amgen is conducted in compliance with all applicable local laws and national and international regulatory standards. To reinforce compliance with the rules, we created a Global Code of Ethics for Clinical Research. In it, we consider adequacy, selection of researchers, ethical review, privacy, quality of clinical data, informed consent, safety monitoring, standard of care, access to experimental drugs, remuneration and transparency.

"Our work within the R&D area is motivated to bring more and more innovative drug options, respecting all legislation and the ethical principles of scientific research. Our mission of Serving Patients is practiced every day in our actions and decisions. We are extremely proud to be part of Amgen!"

ROBERTO MOREIRA, RESEARCH & DEVELOPMENT MANAGER



[VIEW AMGEN'S GLOBAL CODE OF ETHICS FOR CLINICAL RESEARCH HERE](#)



INVESTMENT RESEARCH
AND DEVELOPMENT

**US\$ 4,8
billion**
worldwide

**R\$ 9,7
million**
in Brazil

DATA PRIVACY AND CYBER SECURITY

Our mission to serve patients extends to other areas. We also want to ensure the security and data privacy of each of them. As a pharmaceutical industry, we are a huge database of patient information and clinical data, as well as collaborators, doctors and partners. The topic gained even more relevance with the entry into force of the General Law for the Protection of Personal Data (LGPD) in Brazil.

With valuable data such as the one we deal with, we had to analyze our processes, review aspects of their functioning to give the most appropriate treatment to this data in our operations,

reinforcing their protection in the event of cyber-attacks.

With this focus, during 2021, we seek to mature the cyber protection culture. We created and approved 15 ISRAs (*Information Security Risk Assessment*), mechanisms that identify and evaluate security controls in applications, creating solutions for implementation.

We released more than 10 cyber security announcements, as well as campaigns and training with the team on how to manage privacy incidents.



CREDITS

COORDINATION

Isabela Nunes, Paola de Andrade and Jhonathan Barreto

WRITING, EDITING, CONSULTING AND DESIGN

Approach Communication

PHOTOS

Amgen Collection and Adobe Stock



AMGEN®